Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06897917 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain

Name: Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer Pain — clinical trial record (NCT06897917)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusNot Yet Recruiting

PhasePhase 4

SponsorHenan Cancer Hospital

Started2025-04

View on ClinicalTrials.gov ↗

Record status

This record was last updated March 27, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Henan Cancer Hospital

107 trials monitored

See 2 trials at risk

This study is a prospective, single-arm, multicenter, real-world study to evaluate effect of bowel function, analgesic effect, quality of life, and safety of Mimeixin® in Chinese patients with severe cancer pain.

Trial Details

NCT Number	NCT06897917
Lead Sponsor	Henan Cancer Hospital
Conditions	Opioid-Induced Constipation, Pain Cancer
Enrollment	203 participants
Start Date	2025-04
Primary Completion	2025-12 (estimated)
Study Completion	2025-12 (estimated)
Updated on ClinicalTrials.gov	2025-03-27